Stephen M. Strittmatter
Fondateur chez Renetx Bio, Inc.
Profil
Stephen M.
Strittmatter is the founder of ProteoWise, Inc. (founded in 2018) and Renetx Bio, Inc. (founded in 2009), where he holds the title of Scientific Advisor.
Currently, he is a Director at Allyx Therapeutics, Inc.
Postes actifs de Stephen M. Strittmatter
| Sociétés | Poste | Début |
|---|---|---|
Renetx Bio, Inc.
 Renetx Bio, Inc. BiotechnologyHealth Technology Renetx Bio, Inc. operates as a biotechnology company that develops disease modifying therapeutics. It offers Nogo Receptor and Cellular Prion Protein technology. The company was founded by Sylvia McBrinn and Stephen Strittmatter in 2009 and is headquartered in New Haven, CT. | Fondateur | 01/01/2009 |
Allyx Therapeutics, Inc.
 Allyx Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Allyx Therapeutics is an American clinical-stage biotechnology company founded in 2019 by a group of experienced biopharma industry executives, venture capitalists, and scientific experts. The company is based in an undisclosed location and aims to deliver a novel approach to preserve and protect synapses for people living with neurodegenerative diseases. Its lead compound, alx-001, is a first-in-class oral therapy with a unique mechanism of action at mglur5 currently in clinical development in Alzheimer's disease. The company is developing an oral drug that demonstrates reversal of learning and memory deficits due to Alzheimer's disease. The company was founded by Timothy Siegert, Stephen M. Bloch, Paul R. Fonteyne, and Stephen M. Bloch has been the CEO since incorporation. | Directeur/Membre du Conseil | - |
Anciens postes connus de Stephen M. Strittmatter
| Sociétés | Poste | Fin |
|---|---|---|
ProteoWise, Inc.
 ProteoWise, Inc. BiotechnologyHealth Technology ProteoWise, Inc. engages in the development of biotech technology solutions. It offers a proteomic technology that enables researchers to move beyond western blot and into high-throughput proteomics. The company was founded by Stephen M. Strittmatter and Mikhail Kostylev in 2018 and is headquartered in New Haven, CT. | Fondateur | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Renetx Bio, Inc.
Renetx Bio, Inc. BiotechnologyHealth Technology Renetx Bio, Inc. operates as a biotechnology company that develops disease modifying therapeutics. It offers Nogo Receptor and Cellular Prion Protein technology. The company was founded by Sylvia McBrinn and Stephen Strittmatter in 2009 and is headquartered in New Haven, CT. | Health Technology |
ProteoWise, Inc.
ProteoWise, Inc. BiotechnologyHealth Technology ProteoWise, Inc. engages in the development of biotech technology solutions. It offers a proteomic technology that enables researchers to move beyond western blot and into high-throughput proteomics. The company was founded by Stephen M. Strittmatter and Mikhail Kostylev in 2018 and is headquartered in New Haven, CT. | Health Technology |
Allyx Therapeutics, Inc.
Allyx Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Allyx Therapeutics is an American clinical-stage biotechnology company founded in 2019 by a group of experienced biopharma industry executives, venture capitalists, and scientific experts. The company is based in an undisclosed location and aims to deliver a novel approach to preserve and protect synapses for people living with neurodegenerative diseases. Its lead compound, alx-001, is a first-in-class oral therapy with a unique mechanism of action at mglur5 currently in clinical development in Alzheimer's disease. The company is developing an oral drug that demonstrates reversal of learning and memory deficits due to Alzheimer's disease. The company was founded by Timothy Siegert, Stephen M. Bloch, Paul R. Fonteyne, and Stephen M. Bloch has been the CEO since incorporation. | Commercial Services |